Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics


Allogene Therapeutics, Inc. (ALLO)

Today's Latest Price: $44.22 USD

0.14 (0.32%)

Updated Jul 8 4:00pm

Add ALLO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALLO Daily Price Range
ALLO 52-Week Price Range

ALLO Stock Price Chart Technical Analysis Charts


ALLO Price/Volume Stats

Current price $44.22 52-week high $55.00
Prev. close $44.08 52-week low $17.43
Day low $43.72 Volume 325,866
Day high $44.82 Avg. volume 950,415
50-day MA $41.24 Dividend yield N/A
200-day MA $29.54 Market Cap 5.54B

Allogene Therapeutics, Inc. (ALLO) Company Bio


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.


ALLO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ALLO Latest Social Stream


Loading social stream, please wait...

View Full ALLO Social Stream

Latest ALLO News From Around the Web

Below are the latest news stories about Allogene Therapeutics Inc that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board

The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. “We are privileged to welcome Drs. Gajewski and Grupp to our Scientific Advisory Board,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene.

Yahoo | July 7, 2020

IPO Update: Nkarta Proposes Terms For $150 Million IPO

Quick Take Nkarta (NKTX) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement. The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of development for its...

Donovan Jones on Seeking Alpha | July 5, 2020

Allogene Therapeutics, Inc. (ALLO): Hedge Funds Sticking Around

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 5, 2020

Insider Sells Allogene Therapeutics Shares

Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) moved lower by 2% from the previous closing price. A Form 4 filing filed with the SEC on Monday, June 29 showed that Tpg Group Holdings Sbs) Advisors, Inc. sold 500 shares at $44.01 on Friday, Jun 26, sold 24,904 shares at $43.27 on Monday, Jun 29, and sold 59,747 shares at $42.21 on Tuesday, Jun 30.The transaction moved the executive's stake in Allogene Therapeutics Inc. to 19,800,957 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision.Insiders buying stock after a notable sell off can indicate an insi...

Yahoo | July 1, 2020

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize

Considered one of the highest distinctions in science for researchers working in the Netherlands, a maximum of two Stevin Prizes are awarded by the Dutch Research Council (NWO) each year to a researcher or team whose work has a major social impact. “We are thrilled that Ton, an internationally renowned immunologist and researcher, has been recognized for his outstanding pioneering and inspiring contributions to cancer immunotherapy with the prestigious Stevin Prize,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

Yahoo | July 1, 2020

Read More 'ALLO' Stories Here

ALLO Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8197 seconds.